US-based epigenetic data company Episona has launched its new male fertility test, Seed, at the American Society for Reproductive Medicine Scientific Congress & Expo.
Seed evaluates epigenetic changes in DNA to predict the risk for male factor infertility and poor embryo development, offering physicians and their patients a new tool for personalising fertility treatment and boosting the chances of pregnancy quickly and cost effectively.
Go deeper with GlobalData
Episona president and CEO Alan Horsager said: “Physicians have long relied on the traditional semen analysis as the sole option for determining the male’s role in fertility.
“Seed provides patients with previously missing information about their fertility and we believe this has the potential to transform fertility care.”
“While semen analyses provide valuable information on sperm count, motility and morphology, they offer little insight into the more complex factors related to male fertility or into the male’s role in embryo development.
“By combining the latest advances in science and technology, Seed provides patients with previously missing information about their fertility and we believe this has the potential to transform fertility care.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe new male fertility test is based on the science of epigenetics which involves the assessment of external or environmental factors such as aging, smoking, obesity, environmental exposure and exercise that can change the layer on top of the DNA known as the epigenome.
These DNA modifications alter the gene expressions, or read, which in turn can impact how genes function.
Episona specifically focuses on DNA methylation on the epigenome by examining the differences in methylation between known fertile sperm DNA and infertile sperm DNA.
Seed uses Illumina’s microarrays to analyse more than 480,000 regions on sperm DNA for abnormal methylation at different gene sites, considered important for fertility.
A relative risk is then assigned to each abnormal location for either male factor infertility or poor embryo development.
